Möchten Sie immer auf dem neuesten Stand bleiben?

Ottawa, April 24, 2026 (GLOBE NEWSWIRE) -- Rising global incidence of cancer and cardiovascular diseases is driving demand for advanced diagnostic imaging and targeted radiopharmaceutical therapies....

ITM today announced that it will provide quality of life data from its Phase 3 COMPETE trial in a poster presentation at ASCO 2026.

ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with PNETs at ENETS 2026

ITM today announced that it will provide further post-hoc subgroup analysis data focusing on Pancreatic Neuroendocrine Tumors from its Phase 3 trial

Patent for composition of matter and methods of use of high-radiopure diagnostic ⁶¹Cu-NU101 and combination use with therapeutic pair ⁶⁷Cu-NU101

BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping...

Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine...

Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires...

Curium has established a legal entity in China which represents a major milestone in Curium’s international growth strategy and will enhance Curium’s ability to serve patients with cancer across...

Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shapeBrings over 15 years...